|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 182.26 USD | +2.77% |
|
+3.52% | +3.74% |
| 09:00am | Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma | RE |
| 08:14am | Biogen to Acquire Felzartamab Rights in Greater China From TJ Biopharma | MT |
| Capitalization | 26.03B 22.05B 20.29B 19.2B 35.58B 2,408B 36.21B 238B 93.16B 1,167B 97.63B 95.6B 4,115B | P/E ratio 2026 * |
14.9x | P/E ratio 2027 * | 13.7x |
|---|---|---|---|---|---|
| Enterprise value | 26.61B 22.54B 20.74B 19.63B 36.38B 2,462B 37.01B 243B 95.24B 1,193B 99.81B 97.73B 4,206B | EV / Sales 2026 * |
2.82x | EV / Sales 2027 * | 2.51x |
| Free-Float |
85.5% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biogen Inc.
| 1 day | +2.89% | ||
| 1 week | +3.52% | ||
| Current month | -0.41% | ||
| 1 month | +0.61% | ||
| 3 months | +10.39% | ||
| 6 months | +24.51% | ||
| Current year | +3.74% |
| 1 week | 174.85 |  | 183.69 |
| 1 month | 168.64 | | 192.28 |
| Current year | 160.36 | | 202.41 |
| 1 year | 115.25 | | 202.41 |
| 3 years | 110.04 | | 319.76 |
| 5 years | 110.04 | | 468.55 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 2022-11-13 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 2025-02-28 |
Jane Grogan
CTO | Chief Tech/Sci/R&D Officer | 59 | 2023-10-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 66 | 2023-06-25 |
Eric Rowinsky
BRD | Director/Board Member | 69 | 2010-03-22 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 2009-12-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 1.69% | 2 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.77% | +3.52% | +56.73% | -37.10% | 26.03B | |
| +0.10% | +0.62% | +33.77% | -5.89% | 77.02B | |
| -2.58% | -6.17% | +83.38% | +195.04% | 59.3B | |
| +0.25% | +60.50% | +60.50% | +60.50% | 50.73B | |
| +0.21% | -1.27% | -42.59% | -54.15% | 47.29B | |
| +0.73% | +6.63% | +115.04% | -61.71% | 21.3B | |
| -0.20% | +2.15% | +71.83% | +32.16% | 19.47B | |
| -0.71% | +3.20% | +57.87% | +58.35% | 15.94B | |
| -0.40% | -1.87% | +128.04% | +363.96% | 14.88B | |
| +1.50% | +2.77% | -5.47% | +670.75% | 13.41B | |
| Average | +0.20% | +2.08% | +55.91% | +122.19% | 34.54B | |
| Weighted average by Cap. | -0.09% | +0.94% | +48.30% | +73.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.43B 7.98B 7.35B 6.95B 12.89B 872B 13.11B 86.04B 33.74B 423B 35.36B 34.62B 1,490B | 9.36B 7.93B 7.29B 6.9B 12.79B 866B 13.02B 85.42B 33.49B 420B 35.1B 34.37B 1,479B |
| Net income | 1.84B 1.56B 1.43B 1.36B 2.51B 170B 2.56B 16.78B 6.58B 82.43B 6.89B 6.75B 291B | 2.06B 1.74B 1.61B 1.52B 2.82B 191B 2.86B 18.8B 7.37B 92.37B 7.72B 7.56B 326B |
| Net Debt | 580M 491M 452M 428M 792M 53.63B 806M 5.29B 2.07B 26B 2.17B 2.13B 91.63B | -2.55B -2.16B -1.99B -1.88B -3.48B -236B -3.54B -23.25B -9.12B -114B -9.55B -9.36B -403B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-04-20 | 182.84 $ | +3.10% | 369,683 |
| 26-04-17 | 177.35 $ | +0.76% | 1,239,458 |
| 26-04-16 | 176.02 $ | -2.50% | 953,722 |
| 26-04-15 | 180.54 $ | +0.88% | 1,168,801 |
| 26-04-14 | 178.96 $ | +1.47% | 1,550,580 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
